• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Trypanosomiasis/Sleeping Sickness
    • View Item
    Apr 14, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Treatment of human African trypanosomiasis--present situation and needs for research and development.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    lancet legros HAT.pdf
    Size:
    448.3Kb
    Format:
    PDF
    Download
    Authors
    Legros, D
    Ollivier, G
    Gastellu-Etchegorry, M
    Paquet, C
    Burri, C
    Jannin, J
    Büscher, P
    Affiliation
    Epicentre, Paris, France. dlegros@epicentre.msf.org
    Issue Date
    2002-07
    
    Metadata
    Show full item record
    Journal
    Lancet Infectious Diseases
    Abstract
    Human African trypanosomiasis re-emerged in the 1980s. However, little progress has been made in the treatment of this disease over the past decades. The first-line treatment for second-stage cases is melarsoprol, a toxic drug in use since 1949. High therapeutic failure rates have been reported recently in several foci. The alternative, eflornithine, is better tolerated but difficult to administer. A third drug, nifurtimox, is a cheap, orally administered drug not yet fully validated for use in human African trypanosomiasis. No new drugs for second-stage cases are expected in the near future. Because of resistance to and limited number of current treatments, there may soon be no effective drugs available to treat trypanosomiasis patients, especially second-stage cases. Additional research and development efforts must be made for the development of new compounds, including: testing combinations of current trypanocidal drugs, completing the clinical development of nifurtimox and registering it for trypanosomiasis, completing the clinical development of an oral form of eflornithine, pursuing the development of DB 289 and its derivatives, and advancing the pre-clinical development of megazol, eventually engaging firmly in its clinical development. Partners from the public and private sector are already engaged in joint initiatives to maintain the production of current drugs. This network should go further and be responsible for assigning selected teams to urgently needed research projects with funds provided by industry and governments. At the same time, on a long term basis, ambitious research programmes for new compounds must be supported to ensure the sustainable development of new drugs.
    Publisher
    Elsevier
    URI
    http://hdl.handle.net/10144/18268
    PubMed ID
    12127356
    Additional Links
    http://www.thelancet.com/journals/laninf
    Language
    en
    ISSN
    1473-3099
    Collections
    Trypanosomiasis/Sleeping Sickness

    entitlement

    Related articles

    • Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
    • Authors: Chappuis F
    • Issue date: 2007 Dec 1
    • The treatment of human African trypanosomiasis.
    • Authors: Pépin J, Milord F
    • Issue date: 1994
    • Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    • Authors: Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Karunakara U
    • Issue date: 2007 Dec 1
    • Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    • Authors: Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E, Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U, Torreele E, Kande V
    • Issue date: 2009 Jul 4
    • A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    • Authors: Kansiime F, Adibaku S, Wamboga C, Idi F, Kato CD, Yamuah L, Vaillant M, Kioy D, Olliaro P, Matovu E
    • Issue date: 2018 Feb 22
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.